Stock CRL CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-23 pm EDT 		5-day change 1st Jan Change
240.1 USD +3.26% Intraday chart for Charles River Laboratories International, Inc. +3.35% +1.58%
Apr. 16 Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing CI
Apr. 12 Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278 MT

Evolution of the average Target Price on Charles River Laboratories International, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c3706ab5ac.ie2HmQBwh4VedyCL3wLAmEKUJDVKkfgBNuzlyXwD5Hs.zazpy3AFzPEfM1ntlHGH_S-kcUxz35Beb46m_00uqRekoezVTAntvDQhFA~85cab5d39f91bd9615076d9a8e508fb3

Analyst Recommendations on Charles River Laboratories International, Inc.

Zacks Investment Research Adjusts Charles River Laboratories International's Price Target to $259 From $278 MT
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus MT
Deutsche Bank Raises Price Target on Charles River Laboratories to $300 From $275, Keeps Buy Rating MT
Argus Raises Price Target on Charles River Laboratories International to $290 From $200, Maintains Buy Rating MT
Deutsche Bank Raises Charles River Laboratories International Price Target to $275 From $245, Maintains Buy Rating MT
Morgan Stanley Raises Price Target on Charles River Laboratories International to $235 From $205, Keeps Equalweight Rating MT
TD Cowen Adjusts Charles River Laboratories International's PT to $260 From $193, Keeps Market Perform Rating MT
Stephens Adjusts Charles River Laboratories International's PT to $280 From $270, Keeps Overweight Rating MT
Citigroup Adjusts Price Target on Charles River Laboratories International to $250 From $215, Maintains Neutral Rating MT
UBS Adjusts Charles River Laboratories International Price Target to $290 From $270, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on Charles River Laboratories International to $280 From $270, Maintains Overweight Rating MT
Baird Adjusts Price Target on Charles River Laboratories International to $268 From $252, Maintains Outperform Rating MT
Guggenheim Downgrades Charles River Laboratories International to Neutral From Buy MT
Futures climb after Wall St sell-off; rate-cut jitters loom RE
UBS Adjusts Charles River Laboratories International Price Target to $270 From $215, Maintains Buy Rating MT
Citigroup Adjusts Price Target on Charles River Laboratories to $215 From $190, Keeps Neutral Rating MT
Morgan Stanley Cuts Price Target on Charles River Laboratories to $205 From $220, Maintains Equalweight Rating MT
UBS Cuts Charles River Laboratories International Price Target to $215 From $250, Maintains Buy Rating MT
Deutsche Bank Adjusts Charles River Laboratories International Price Target to $215 From $236, Maintains Buy Rating MT
Morgan Stanley Cuts Charles River Laboratories International's Price Target to $220 From $235, Keeps Equalweight Rating MT
TD Cowen Cuts Charles River Laboratories' Price Target to $209 From $212, Maintains Market Perform Rating MT
Guggenheim Adjusts Price Target on Charles River Laboratories International to $225 From $255, Maintains Buy Rating MT
UBS Adjusts Charles River Laboratories International Price Target to $250 From $255, Maintains Buy Rating MT
Wells Fargo Adjusts Charles River Laboratories International Price Target to $275 From $280, Maintains Overweight Rating MT
TD Cowen Initiates Coverage on Charles River Laboratories International With Market Perform Rating, $212 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
240.1 USD
Average target price
270.7 USD
Spread / Average Target
+12.72%
High Price Target
300 USD
Spread / Highest target
+24.93%
Low Price Target
235 USD
Spread / Lowest Target
-2.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Charles River Laboratories International, Inc.

Zacks Investment Research
Deutsche Bank Securities
Argus
Morgan Stanley
TD Cowen
Stephens Inc.
Citigroup
UBS
Baird
JPMorgan Chase
Guggenheim
Wells Fargo Securities
BofA Securities
Jefferies & Co.
Credit Suisse
Evercore ISI
KeyBanc Capital Markets
Truist Securities
Goldman Sachs
J.P. Morgan Chase

Ratings for Charles River Laboratories International, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. Consensus Charles River Laboratories International, Inc.